Suppr超能文献

2004 年世卫组织/国际泌尿病理学会分类对预测非肌肉浸润性膀胱尿路上皮肿瘤的复发、进展和癌症特异性死亡率的预后意义:1515 例临床病理研究。

Prognostic significance of the 2004 WHO/ISUP classification for prediction of recurrence, progression, and cancer-specific mortality of non-muscle-invasive urothelial tumors of the urinary bladder: a clinicopathologic study of 1,515 cases.

机构信息

Department of Pathology, Taipei Veterans General Hospital, No. 201, Shi-Pai Rd, Sec 2, Taipei, 11217 Taiwan.

出版信息

Am J Clin Pathol. 2010 May;133(5):788-95. doi: 10.1309/AJCP12MRVVHTCKEJ.

Abstract

To verify prognostic significance of the 2004 World Health Organization (WHO)/International Society of Urological Pathology (ISUP) grading systems, we retrospectively studied the tumors of 1,515 patients who underwent transurethral resection of primary non-muscle-invasive urothelial tumors (pTa, 1,006 patients; pT1, 509 patients) confined to the bladder. Cases were classified according to the 2004 WHO/ISUP systems as 212 cases of papillary urothelial neoplasm of low malignant potential (PUNLMP), 706 low-grade papillary urothelial carcinomas (LPUCs), and 597 high-grade papillary urothelial carcinomas (HPUCs). PUNLMP showed the statistically significantly lowest recurrence cumulative incidence compared with the other tumor types. There were significant differences and trends for higher progression and cancer-specific mortality cumulative incidence in the following order: PUNLMP, LPUC, pTa HPUC, and pT1 HPUC. No differences of progression and cancer-specific mortality cumulative incidence were found between pTa and pT1 LPUC. Our study validates the usefulness of the 2004 WHO/ISUP system to classify urothelial tumors into prognostically distinct categories that would contribute to the design of therapeutic and monitoring strategies for patients with non-muscle-invasive bladder urothelial tumors.

摘要

为了验证 2004 年世界卫生组织(WHO)/国际泌尿病理学会(ISUP)分级系统的预后意义,我们回顾性研究了 1515 例接受经尿道膀胱非肌肉浸润性尿路上皮肿瘤(pTa,1006 例;pT1,509 例)切除术的患者的肿瘤。根据 2004 年 WHO/ISUP 系统,这些病例被分为 212 例低恶性潜能的乳头状尿路上皮肿瘤(PUNLMP)、706 例低级别乳头状尿路上皮癌(LPUC)和 597 例高级别乳头状尿路上皮癌(HPUC)。PUNLMP 的复发累积发生率明显低于其他肿瘤类型。在进展和癌症特异性死亡率累积发生率方面存在显著差异和趋势,其顺序如下:PUNLMP、LPUC、pTa HPUC 和 pT1 HPUC。pTa 和 pT1 LPUC 之间在进展和癌症特异性死亡率累积发生率方面无差异。我们的研究验证了 2004 年 WHO/ISUP 系统将尿路上皮肿瘤分为具有不同预后的类别是有用的,这有助于为非肌肉浸润性膀胱尿路上皮肿瘤患者制定治疗和监测策略。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验